Ocugen Secures Funding to Advance Key Gene Therapy Trials
30.01.2026 - 16:59:05 | boerse-global.de
Biotechnology firm Ocugen has bolstered its financial position through a recent capital raise, providing crucial resources as it approaches significant clinical milestones. The company has extended its financial runway into the fourth quarter of 2026, securing $22.5 million in new funding. This strategic move comes at a pivotal moment for the company’s development pipeline.
On January 23, 2026, Ocugen completed the placement of 15 million new shares at $1.50 per share. After accounting for commissions and associated expenses, the net proceeds to the company are approximately $20.85 million. The capital raise was led by RTW Investments, with participation from both existing shareholders and new institutional investors.
Management has indicated that these funds are allocated for Read more...
